Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly report filed with the U.S. Securities and Exchange Commission on Nov. 14, 2025 (SEC filing). The fund’s total reportable U.S. equity assets stood at $182.61 million across six holdings after the filing.Cytokinetics, Incorporated is a late-stage biopharmaceutical company specializing in muscle biology, with a pipeline of novel therapies in advanced clinical development. The company leverages proprietary expertise in muscle contractility to address unmet medical needs in serious cardiovascular and neuromuscular diseases. Strategic alliances and a focused R&D approach position Cytokinetics to compete in the biotechnology sector targeting high-impact therapeutic areas.Foresite's bet on Cytokinetics in the third quarter was a relatively big one for the fund. It was the only new position added in the third quarter. Despite being a new addition, it was the fund's second-largest holding with a value of $25.2 million at the end of September. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool